Garry Watts is to succeed Dr John Brown as non-executive chairman of BTG, an international specialist healthcare company, on 1 January 2012.
Watts is chairman of the Spire Healthcare group of private hospitals. He is also the senior independent director at Stagecoach Group and a non-executive director of Coca-Cola Enterprises.
He was chief executive of SSL International for seven years until its sale in November 2010 to Reckitt Benckiser. He was a member of the supervisory board of the UK's Medicines Healthcare Research Agency for 17 years until 2008 and is a former executive director of Medeva and Celltech. He was also a non-executive director of Protherics until its acquisition by BTG in December 2008.
Louise Makin, chief executive of BTG, commented: ‘On behalf of the board, I'd like to thank John for his enormous contribution to BTG’s development, including his overall stewardship of the business and the support he has given to us all throughout his tenure as chairman.
‘Garry brings a wealth of experience from the healthcare and other sectors that will be of great benefit to BTG and we all look forward to working with him.’
BTG names non-executive chairman
Former chief executive of SSL International joins healthcare firm
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
2011 nces focus on cancer therapies
The future of the pharma industry increasingly lies in drugs for diseases with smaller patient populations, and those targeted more precisely at specific patient sub-populations. Many of the new chemical entities approved in 2011 were targeted at cancer, diabetes and cardiovascular diseases, as well as bacterial and viral infections
Research & Development
ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development
Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease
Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing
LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations
Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026